Jasper Therapeutics director resigns from board
Jasper Therapeutics, Inc. reported a governance change as director Christian Nolet resigned from the Board of Directors and the Board committees on which he served, effective May 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Jasper Therapeutics, Inc. reported a governance change as director Christian Nolet resigned from the Board of Directors and the Board committees on which he served, effective May 15, 2026. The company stated that his resignation was not due to any disagreement regarding its operations, policies, or practices.
The Board appointed Svetlana Lucas, Ph.D. as a member of the Board’s Audit Committee. The filing also reiterates that Jasper’s voting common stock, with a par value of $0.0001 per share, trades on Nasdaq under the symbol JSPR, and its redeemable warrants trade under JSPRW.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Notice Date of resignation: May 15, 2026
CEO signature date: May 21, 2026
Common stock par value: $0.0001 per share
+2 more
5 metrics
Notice Date of resignation
May 15, 2026
Effective date of Christian Nolet’s board and committee resignation
CEO signature date
May 21, 2026
Date Jeet Mahal signed the report as Chief Executive Officer
Common stock par value
$0.0001 per share
Par value of Jasper Therapeutics voting common stock
Warrant exercise price
$115.00 per share
Exercise price for one share of voting common stock via redeemable warrants
Warrant-to-share ratio
10 warrants for 1 share
Each ten redeemable warrants exercisable for one share of voting common stock
Key Terms
Emerging growth company, Audit Committee, Redeemable Warrants, Inline Extensible Business Reporting Language (iXBRL), +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Audit Committee financial
"The Board has appointed Svetlana Lucas, Ph.D. as a member of the Audit Committee of the Board."
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Redeemable Warrants financial
"Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00"
A redeemable warrant is a tradable right that lets its holder buy a company’s shares at a fixed price before a set date, but the issuer has the contract power to cancel (redeem) the warrant early under agreed terms. For investors this matters because early redemption can force decision-making, change the timing of when new shares might be created, and affect potential gains or dilution—much like a store coupon that the issuer can cancel by paying you off instead of letting you use it.
Inline Extensible Business Reporting Language (iXBRL) technical
"Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)."
Voting Common Stock financial
"Voting Common Stock, par value $0.0001 per share | | JSPR | | The Nasdaq Stock Market LLC"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Jasper Therapeutics (JSPR) disclose?
Jasper Therapeutics disclosed that director Christian Nolet resigned from the Board and the committees on which he served, effective May 15, 2026. The company noted the resignation was not due to any disagreement over operations, policies, or practices.
Why did Christian Nolet resign from Jasper Therapeutics’ board?
Jasper Therapeutics stated that Christian Nolet’s resignation was not the result of any disagreement with the company regarding its operations, policies, or practices. The filing provides no additional reasons, emphasizing only the absence of conflict-related issues.
Who was appointed to Jasper Therapeutics’ Audit Committee?
The Board appointed Svetlana Lucas, Ph.D. as a member of the Audit Committee. This appointment follows the resignation of director Christian Nolet from the Board and the committees on which he served, effective May 15, 2026, as disclosed in the filing.
What securities of Jasper Therapeutics are listed on Nasdaq?
Jasper Therapeutics lists its voting common stock, par value $0.0001 per share, under the symbol JSPR, and its redeemable warrants, each ten warrants exercisable for one share at $115.00, under the symbol JSPRW on The Nasdaq Stock Market LLC.
What is the exercise structure of Jasper Therapeutics’ redeemable warrants?
Each Jasper Therapeutics redeemable warrant trading under JSPRW represents the right where ten warrants are exercisable for one share of voting common stock at an exercise price of $115.00 per share, as described in the company’s disclosure.
Who signed the Jasper Therapeutics 8-K reporting this board change?
The report was signed on behalf of Jasper Therapeutics, Inc. by Jeet Mahal, who is identified as the company’s Chief Executive Officer. The signature block is dated May 21, 2026, confirming official authorization of the disclosed information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates